Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes

European Urology Oncology(2025)10.1016/j.euo.2025.01.002Source: DataRank Database

Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes is a research paper published in European Urology Oncology (2025). On theSindex it has a DataRank of 0.292. It has been cited 6 times.

N/A

0.292DataRank · unranked

Scored on demand from live citation data

Open Access6 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (26 grants)Impact (FWCI 4.20)OA: greenTopics (53)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.292

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (20)

Abuzar Moradi Tuchayi,Soon Khai Low ORCID,Ali T. Arafa,Laura Graham ORCID,Roman Gulati ORCID

Live enrichment

PubMed:39920014 PMC:PMC12325686 OpenAlex:https://openalex.org/W4407209225

National Institutes of Health

Grant: PC200262P1

National Institutes of Health

Grant: P30CA015704

National Institutes of Health

Grant: R50CA22183

National Institutes of Health

Grant: P30CA077598

National Institutes of Health

Grant: R01CA281801-02

National Institutes of Health

Grant: R35CA274442

National Institutes of Health

Grant: R01CA235741

National Institutes of Health

Grant: CA280056

National Institutes of Health

Grant: U24CA26404403

National Institutes of Health

Grant: K12CA086913

National Institutes of Health

Grant: P50CA097186

National Institutes of Health

Grant: 5T32CA009515-33

TRAINING IN CANCER BIOLOGY AND TRANSPLANTATION

National Institutes of Health

Grant: R01CA21214

National Institutes of Health

Grant: R21CA277368

National Institutes of Health

Grant: R37 CA286450

US Department of Defense

Grant: W81XWH-17-2-0043

US Department of Defense

Grant: W81XWH-22-2-0025

US Department of Defense

Grant: W81XWH-21-1-0265

American Cancer Society

Grant: PF-23-1153194-01-CDP

NCI NIH HHS

Grant: R01 CA212148

NCI NIH HHS

Grant: R01 CA280056

NCI NIH HHS

Grant: T32 CA009515

NCI NIH HHS

Grant: R01 CA281801

NCI NIH HHS

Grant: R50 CA221836

Prostate Cancer Foundation

Institute for Prostate Cancer Research

FWCI

4.20

Citation Percentile

0.9%

Citation Trend

2025

2026

greenLicense: Elsevier TDM

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12325686/

publisherhttps://api.elsevier.com/content/article/PII:S2588931125000021?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2588931125000021?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.euo.2025.01.002

Fields of Study

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapyProstate Cancer Diagnosis and Treatment03 medical and health sciences0302 clinical medicineHumansMaleProstatic Neoplasms, Castration-ResistantRetrospective StudiesAgedPoly(ADP-ribose) Polymerase InhibitorsMutationMiddle AgedDipeptidesRecombinational DNA RepairTreatment OutcomeProstate-Specific AntigenAged, 80 and overLutetium

MeSH Terms

Poly(ADP-ribose) Polymerase InhibitorsAgedAged, 80 and overDipeptidesHumansLutetiumMaleMiddle AgedMutationRetrospective StudiesTreatment OutcomeProstate-Specific AntigenRecombinational DNA RepairProstatic Neoplasms, Castration-Resistant

Keywords

PARP inhibitorMedicineProstate cancerPoly ADP ribose polymeraseDNA repairHomologous recombinationGeneCancer researchOncologyGeneticsInternal medicineCancerBiologyDNA damage repairProstate-specific membrane antigenATM geneBrca2 GeneMetastatic Prostate Cancer(177)Lu-psma-617Article

Sustainable Development Goals

SDG 0: Good health and well-being